Metraipolis › archive › dc_48a94fc25484
Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42495108
- DOI
- 10.1016/j.eclinm.2026.104073
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T03:24:28.806Z
- SHA-256 of the archived text
932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312- Stable URL of this page
https://metraipolis.com/documento/dc_48a94fc25484
How to cite
Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108 — Europe PMC (en), https://europepmc.org/article/MED/42495108 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_48a94fc25484 (Metraipolis archive dc_48a94fc25484, sha256 932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312)
BibTeX
@misc{dc48a94fc25484,
title = {Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42495108},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_48a94fc25484; sha256 932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495108. Agents can read the archived copy with the MCP tool read_document.